share_log

Declining Stock and Decent Financials: Is The Market Wrong About Yunnan Baiyao Group Co.,Ltd (SZSE:000538)?

Declining Stock and Decent Financials: Is The Market Wrong About Yunnan Baiyao Group Co.,Ltd (SZSE:000538)?

股票下跌和财务状况良好:市场对云南白药集团股份有限公司的看法是错误的吗, Ltd(深圳证券交易所代码:000538)?
Simply Wall St ·  2023/12/05 17:27

It is hard to get excited after looking at Yunnan Baiyao GroupLtd's (SZSE:000538) recent performance, when its stock has declined 8.9% over the past three months. But if you pay close attention, you might find that its key financial indicators look quite decent, which could mean that the stock could potentially rise in the long-term given how markets usually reward more resilient long-term fundamentals. Particularly, we will be paying attention to Yunnan Baiyao GroupLtd's ROE today.

看着云南白药集团有限公司(深交所代码:000538)最近的表现,很难感到兴奋,当时该公司的股票在过去三个月中下跌了8.9%。但是,如果你密切关注,你可能会发现其关键财务指标看起来相当不错,鉴于市场通常会奖励更具弹性的长期基本面,这可能意味着该股有可能长期上涨。特别是,我们今天将关注云南白药集团有限公司的投资回报率。

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.

股本回报率或投资回报率是股东需要考虑的重要因素,因为它可以告诉他们资本再投资的有效性。简而言之,投资回报率显示了每美元从其股东投资中产生的利润。

View our latest analysis for Yunnan Baiyao GroupLtd

查看我们对云南白药集团有限公司的最新分析

How Do You Calculate Return On Equity?

你如何计算股本回报率?

The formula for return on equity is:

股本回报率的公式是:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回报率 = 净利润(来自持续经营业务)÷ 股东权益

So, based on the above formula, the ROE for Yunnan Baiyao GroupLtd is:

因此,根据上述公式,云南白药集团有限公司的投资回报率为:

12% = CN¥4.8b ÷ CN¥40b (Based on the trailing twelve months to September 2023).

12% = 48亿元人民币 ¥40亿元人民币(基于截至2023年9月的过去十二个月)。

The 'return' is the profit over the last twelve months. That means that for every CN¥1 worth of shareholders' equity, the company generated CN¥0.12 in profit.

“回报” 是过去十二个月的利润。这意味着,每持有价值1元人民币的股权,公司就会产生0.12元人民币的利润。

Why Is ROE Important For Earnings Growth?

为什么投资回报率对收益增长很重要?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.

我们已经确定,投资回报率是衡量公司未来收益的有效盈利指标。根据公司选择将多少利润进行再投资或 “保留”,我们便能够评估公司未来创造利润的能力。一般而言,在其他条件相同的情况下,股本回报率和利润留存率高的公司的增长率要高于不具有这些属性的公司。

A Side By Side comparison of Yunnan Baiyao GroupLtd's Earnings Growth And 12% ROE

云南白药集团有限公司收益增长和12%投资回报率的并行比较

To begin with, Yunnan Baiyao GroupLtd seems to have a respectable ROE. Further, the company's ROE compares quite favorably to the industry average of 8.4%. As you might expect, the 2.7% net income decline reported by Yunnan Baiyao GroupLtd is a bit of a surprise. Therefore, there might be some other aspects that could explain this. These include low earnings retention or poor allocation of capital.

首先,云南白药集团有限公司似乎拥有可观的投资回报率。此外,该公司的投资回报率与行业平均水平的8.4%相比相当不错。正如你所预料的那样,云南白药集团有限公司报告的净收入下降2.7%,这有点令人惊讶。因此,可能还有其他一些方面可以解释这一点。其中包括收益保留率低或资本分配不当。

So, as a next step, we compared Yunnan Baiyao GroupLtd's performance against the industry and were disappointed to discover that while the company has been shrinking its earnings, the industry has been growing its earnings at a rate of 11% over the last few years.

因此,下一步,我们将云南白药集团有限公司的业绩与行业进行了比较,结果失望地发现,尽管该公司一直在缩减收益,但该行业在过去几年中一直以11%的速度增长收益。

past-earnings-growth
SZSE:000538 Past Earnings Growth December 5th 2023
深交所:000538 过去的收益增长 2023 年 12 月 5 日

Earnings growth is an important metric to consider when valuing a stock. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is 000538 fairly valued? This infographic on the company's intrinsic value has everything you need to know.

收益增长是估值股票时要考虑的重要指标。对于投资者来说,重要的是要知道市场是否影响了公司的预期收益增长(或下降)。通过这样做,他们将知道这只股票是进入清澈的蓝色海水还是沼泽水域在等着你。000538 的估值是否公平?这张关于公司内在价值的信息图包含了你需要知道的一切。

Is Yunnan Baiyao GroupLtd Efficiently Re-investing Its Profits?

云南白药集团有限公司是否有效地将利润再投资?

With a high three-year median payout ratio of 78% (implying that 22% of the profits are retained), most of Yunnan Baiyao GroupLtd's profits are being paid to shareholders, which explains the company's shrinking earnings. With only a little being reinvested into the business, earnings growth would obviously be low or non-existent.

云南白药集团有限公司的三年期中位派息率很高,为78%(这意味着保留了22%的利润),其大部分利润都支付给了股东,这解释了该公司收益萎缩的原因。如果只对业务进行少量再投资,收益增长显然会很低或根本不存在。

Moreover, Yunnan Baiyao GroupLtd has been paying dividends for at least ten years or more suggesting that management must have perceived that the shareholders prefer dividends over earnings growth. Based on the latest analysts' estimates, we found that the company's future payout ratio over the next three years is expected to hold steady at 76%. Therefore, the company's future ROE is also not expected to change by much with analysts predicting an ROE of 12%.

此外,云南白药集团有限公司派发股息已有至少十年或更长时间,这表明管理层一定已经意识到,股东更喜欢分红而不是收益增长。根据分析师的最新估计,我们发现该公司未来三年的派息率预计将稳定在76%。因此,预计该公司未来的投资回报率也不会有太大变化,分析师预测投资回报率为12%。

Conclusion

结论

Overall, we feel that Yunnan Baiyao GroupLtd certainly does have some positive factors to consider. Although, we are disappointed to see a lack of growth in earnings even in spite of a high ROE. Bear in mind, the company reinvests a small portion of its profits, which means that investors aren't reaping the benefits of the high rate of return. Having said that, looking at current analyst estimates, we found that the company's earnings growth rate is expected to see a huge improvement. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

总体而言,我们认为云南白药集团有限公司确实有一些积极因素需要考虑。但是,尽管投资回报率很高,但我们对收益仍缺乏增长感到失望。请记住,该公司将其利润的一小部分进行再投资,这意味着投资者没有从高回报率中受益。话虽如此,从分析师目前的估计来看,我们发现该公司的收益增长率有望大幅改善。这些分析师的预期是基于对该行业的广泛预期,还是基于公司的基本面?点击此处进入我们分析师对公司的预测页面。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发